Blood-based detection of lung cancer using cysteine-rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study

Lucija Aćkar1, Swaantje Casjens2, Antje Andreas1, Irina Raiko2, Thomas Brüning2, Maria Geffken3, Sven Peine3, Jens Kollmeier4, Georg Johnen2, Kai Bartkowiak1, Daniel Gilbert Weber2 and Klaus Pantel1

1 Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
2 Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Germany
3 Department of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Germany
4 Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany

Keywords
biomarker; cancer; CYR61; liquid biopsy; lung cancer; plasma

Correspondence
K. Pantel, Department for Tumor Biology, University Medical Centre Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
Fax: +49 40 7410 55374
Tel: +49 40 7410 53503
E-mail: pantel@uke.de

Daniel Gilbert Weber and Klaus Pantel contributed equally to this article

Received 28 April 2021, revised 27 July 2021, accepted 9 September 2021, available online 3 October 2021

doi:10.1002/1878-0261.13099

1. Introduction

Lung cancer is the most often diagnosed cancer and the main cause of cancer deaths in the world compared with other tumor entities. To date, the only screening method for high-risk lung cancer patients is low-dosed computed tomography which still suffers from high false-positive rates and overdiagnosis. Therefore, there is an obvious need to identify biomarkers for the detection of lung cancer that could be used to guide the use of low-dosed computed tomography or other imaging procedures. We aimed to assess the performance of the protein cysteine-rich angiogenic inducer 61 (CYR61) as a circulating biomarker for the detection of lung cancer. CYR61 concentrations in plasma were significantly elevated in 87 lung cancer patients (13.7 ± 18.6 ng·mL⁻¹) compared with 150 healthy controls (0.29 ± 0.22 ng·mL⁻¹). Subset analysis stratified by sex revealed increased CYR61 concentrations for adenocarcinoma and squamous cell carcinoma in men compared with women. For male lung cancer patients versus male healthy controls, the sensitivity was 84% at a specificity of 100%, whereas for females, the sensitivity was 27% at a specificity of 99%. The determination of circulating CYR61 protein in plasma might improve the detection of lung cancer in men. The findings of this pilot study support further verification of CYR61 as a biomarker for lung cancer detection in men. Additionally, CYR61 is significantly elevated in women but sensitivity and specificity for CYR61 are too low for the improvement of the detection of lung cancer in women.

Abbreviations
AUC, area under the curve; CI, confidence interval; CYR61, cysteine-rich angiogenic inducer 61; ELISA, enzyme-linked immunosorbent assay; IARC, International Agency for Research on Cancer; IQR, interquartile range; PBMC, peripheral blood mononuclear cells; YI, Youden’s index.
diagnosed LC, respectively [2]. In NSCLC, the most frequently diagnosed histological subtypes are adenocarcinoma (ADC, 40–50% of diagnoses) and squamous cell carcinoma (SCC, 20–30% of diagnoses) [3].

The only screening method seeming suitable for high-risk LC patients is low-dosed computed tomography (LDCT) [4]. The use of appropriate multivariable risk prediction models significantly affects the sensitivity and specificity of LDCT. For example, the US National Lung Screening Trial (NLST) involved current and former heavy smokers (≥ 30 packs per year of cigarette smoking history; former smokers were included if they quit smoking < 15 years before) aged 55–74 years. The participants underwent three annual rounds of LDCT or single-view chest radiography, and LC was identified at baseline in 1.03% of participants [5]. The UK Lung Cancer Screening (UKLS) trial involved participants with a 5-year LC risk of ≥5% according to the Liverpool Lung Project (LLP) multivariable risk prediction model, together with an age of 50–75 years. Participants underwent LDCT-based screening or no screening, and 1.7% of participants were identified with LC [5]. In the NELSON trial, participants were current and former heavy smokers (≥30 packs per year) aged 55–75 who underwent several rounds of LDCT-based screening or no screening and 0.9% of participants were identified with LC [5]. Despite encouraging recent results, LDCT suffers still from high false-positive rates and overdiagnosis [6]. Moreover, intensive evaluations following a positive LDCT are associated with more procedure-related adverse events, higher mean radiation exposure and higher mean health expenditure [7].

Thus, there is an obvious need to identify biomarkers for the detection of LC that could be used to guide the use of LDCT or other imaging procedures. Incorporation of blood biomarkers (‘liquid biopsy’) into the prediction models might have the potential to increase precision of LDCT-based LC screening.

Mutations and gene methylation related to LC, such as mutations in TP53, EGFR, BRAF, ERBB2, PDGFRA and KRAS or methylation of PTGER4/SHOX2, were previously detected in plasma or cerebrospinal fluid of NSCLC and SCLC patients, both in early and late stages [4,8–10]. Moreover, circulating tumor cells (CTCs) have been investigated for early LC detection [11] but a recent validation trial showed that despite initially encouraging results [12], CTCs captured by the ISET method failed to provide sufficient accuracy [13]. New members of the liquid biopsy family applied for LC detection include tumor-macrophage fusion cells (TMF) [14], circulating microRNAs (miRNAs) [15], tumor-educated platelets [16], and extracellular vesicles (EVs) [17]. Proteomic profiling of EVs showed that EVs are packed in a tumor-specific manner [18,19]. Exosome number or presence of certain miRNAs can also indicate the presence of NSCLC [20].

In the present study, we assessed the potential value of CYR61 in plasma as a biomarker for the detection of LC. CYR61 belongs to the CCN family which has six members: CYR61 (CCN1), CTGF (CCN2), NOV (CCN3), WISP-1 (CCN4), WISP-2 (CCN5), and WISP-3 (CCN6). These proteins have modular architecture which consists of an N-terminal signal sequence followed by domains with sequence similarity to insulin-like growth factor-binding protein, von Willebrand factor C, thrombospondin type 1, and a cysteine knot at the C terminus. The exception is WISP-2, which lacks the C-terminal region [21,22]. CCN proteins are secreted extracellular proteins associated with matrix, and they are involved in both, internal and external cellular signaling [21]. CYR61 is involved in cell adhesion, cell migration, stimulation of chemotaxis, enhancement of growth factor-induced DNA synthesis, cell survival, and angiogenesis [23].

The role of CYR61 in LC is still under investigation with controversial results. Several authors reported that mRNA levels of CYR61 were decreased in lung tumors compared with normal matched lung tissue [21,24,25] and its overexpression decreases colony formation, reduces proliferation, and leads to growth arrest through the p53-c-myc-beta catenin pathway in LC cells [25–27]. In contrast, CYR61 has been shown to promote epithelial-to-mesenchymal transition, cell viability, tumor growth, and metastasis [27–30].

Elevated CYR61 concentrations have been found in patients with asbestos-related diseases [31], and CYR61 is also a tumor-promoting factor in breast, ovarian, and gastric cancer as well as in gliomas and pancreatic neuroendocrine tumors [22,32–39].

To the best of our knowledge, this is the first report on circulating CYR61 protein in LC. We compared circulating CYR61 concentrations in plasma of patients with LC and healthy controls, and our pilot study provided the first evidence for a sex-dependent effect of CYR61 on the detection of LC.

2. Materials and methods

A detailed description of the methods and experiments is provided in the online Data Supplement.

2.1. Cell lines and culture conditions

The disseminated tumor cell (DTC) cell line from the bone marrow of a LC patient LC-M1 was generated
1994 and authenticated by Klaus Pantel [40,41]. LC-M1 was authenticated using a keratin/vimentin double staining in May 2015 and was essentially cultivated as described before [42]. Previous reports describe the authentication, generation and the attributes of the generated DTC cell lines [40,41,43–45]. LC-M1 was cultured at 37 °C in a humidified environment with 5% of carbon dioxide and 10% of oxygen. Nitrogen served for the adjustment of the oxygen concentration. LC-M1 was cultured in Roswell Park Memorial Institute (RPMI) 1640 medium with added 2 mM L-glutamine, 10 mg·L⁻¹ insulin, 5.5 mg·L⁻¹ transferrin (all from Life Technologies, Darmstadt, Germany), 10% fetal bovine serum, 10 µg·L⁻¹ human basic fibroblast growth factor (b-FGF, Miltenyi Biotec, Bergisch Gladbach, Germany), and 50 µg·L⁻¹ epidermal growth factor (EGF; Miltenyi Biotec).

For the authentication of the cell lines, multiplex cell authentication (SNP-Profiling) by Multiplexion, Heidelberg, Germany, was performed. The last authentication for H1395 was done in May 2015 and for H1299 in June 2018. HCC-366 was obtained from the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ, Braunschweig, Germany) in September 2018. H1993 and H1395 were kindly provided by Carsten Müller-Tidow and H1299 by Harriet Wikman.

The cultivation of H1395, H1299, HCC-366, and LC-M1 was performed in RPMI 1640 with 10% fetal bovine serum and 2 mM L-glutamine (all from Life Technologies), and all cell lines were kept at 37 °C in a humidified environment in the presence of 5% CO₂. The analyzed samples here were generated within 6 months after revitalization of the cell lines.

### 2.2. Cell harvest and sample procurement for western blot

Prior to cell harvest, the cells were washed with 37 °C prewarmed phosphate-buffered saline three times. Subsequently, the cells were collected in 300 µL of lysis mix (9.8 mM urea, 15 mM EDTA, 30 mM Tris) per 75-cm² cell culture flask. The cells were disrupted on ice using the ultrasonic device UP50H (Hielscher, Teltow, Germany) by 3 identical steps (amplitude 100%; 10 s). After incubation at room temperature for 1 h, the cell extract was clarified from insoluble debris by centrifugation (15 000 g at room temperature for 5 min) and collection of the supernatant.

The protein concentration was determined using the Pierce BCA Protein Assay Kit (Pierce, Rockford, TN, USA) according to the manufacturer’s instructions and using BSA as the standard. The samples were stored at −80 °C.

### 2.3. SDS/PAGE and western blot

For the separation of the proteins, a Laemmli buffer system and 10% polyacrylamide gels were used. For the gel runs, either the Protean xi cell (Bio-Rad, Hercules, CA, USA) or the Novex XCell Sure-Lock mini system (Invitrogen, Groningen, the Netherlands) was used. From each cell extract, 20 µg of samples was diluted in SDS sample buffer, heat-denatured at 95 °C for 5 min, and loaded onto the gels. The molecular size standard was the peqGOLD protein-marker V (Peqlab, Erlangen, Germany).

For the protein transfer to FluoroTrans W membranes (Pall, Port Washington, WI, USA), the mini VE vertical electrophoresis system (GE Healthcare, Munich, Germany) was used. Subsequently, the membranes were blocked with 5% low-fat powdered milk (Roth, Karlsruhe, Germany) in TBST (blocking buffer) on a rocker for 1 h. The following primary antibodies were applied. From Cell Signaling Technology (Danvers, MA, USA): anti-alpha-Tubulin antibody, rabbit monoclonal (clone 11H10), dilution 1 : 10 000; anti-CYR61 antibody rabbit monoclonal (clone D4H5D), dilution of 1 : 2000; anti-Integrin β3 antibody, rabbit monoclonal (clone D7X3P), dilution 1 : 2000. From BD Biosciences (Heidelberg, Germany): Anti-Integrin αv antibody, mouse monoclonal (clone 21/CD51), dilution 1 : 500. For the dilution of the primary antibodies, blocking buffer was used and the membranes were incubated with the primary antibody dilution buffer on a roller at 4 °C over night. The secondary antibodies conjugated with horseradish peroxidase (all from DAKO, Glostrup, Denmark) were diluted at a 1 : 1000 dilution in blocking buffer and applied onto the membranes for 90 min at room temperature. The signals were detected by using the Signal Fire ECL Reagent (Cell Signaling Technology) and X-ray films (Agfa Health Care, Mortsel, Belgium) according to the manufacturer’s instructions. X-ray films were digitized using the GS-700 imaging densitometer (Bio-Rad). Each sample was analyzed in three biological triplicates.

### 2.4. ELISA on cell lines

Cell culture supernatant of cell lines was clarified by centrifugation at 2500 g for 15 min. One microliter of cell culture supernatant was applied for ELISA. For whole cell lysate of cell lines, the cells were lysed with LPiP buffer (140 mM NaCl, 50 mM Tris HCl, pH 7.5, 1 mM EDTA, 0.05% NP40, 10% glycerol) and 10 µg of cell lysates was applied. The diluent was PBS (Gibco/Life Technologies, Paisley, UK). The protein
concentration was determined using the Pierce BCA Protein Assay Kit (Pierce) according to the manufacturer’s instructions and using BSA as the standard.

For the analysis of the CYR61 secretion kinetics in H1993 and LC-M1, the cells were cultured in T25 cm² cell culture flasks.

The cells were allowed to settle on the flasks for 48 h. Next, the culture medium was changed and left on the cells for the indicated duration of time. After that, the cell number in the culture flasks was determined, the volume of the cell culture medium was determined, and the cell culture medium was analyzed for CYR61 by ELISA. One microliter of cell culture supernatant was applied for time points 1 h, 3 h, and 5 h. For the time points 5 min, 15 min, and 30 min, 10 µL of cell culture supernatant was applied.

The cell numbers were determined by seeding the cell lines in six-well plates in parallel. For each well, 15 000 to 25 000 cells were seeded and allowed to grow for 24 h. The starting cell number was determined by counting the cell number of one well. Detachment of the cell was done by trypsinization and transfer to a Neubauer counting chamber. Dead cells were detected by using the vital stain trypan blue (Sigma-Aldrich, St. Louis, MO, USA). The cell number per well was calculated for these values. The obtained cell number was taken as the starting cell number (t = 0 h) for the individual experiment. For the other time points, cells were cultivated in additional wells in parallel and processed as described for each experiment. After the appropriate time points, the cells were harvested and counted.

2.5. Generation of calibration curves for CYR61

For the generation of calibration curves, recombinant Cyr61 was spiked into the plasma of healthy donors who are negative for Cyr61. For all wells, unspecific background was eliminated by subtraction of OD values of wells containing cell culture medium. The conversion of the OD450 values from the standard curve to CyR61 amounts was done by linear regression analysis using ORIGINPRO version 9.6.5.169 (OriginLab Corporation, Northampton, MA, USA) (Fig. S1). For the analysis of cell lines, recombinant Cyr61 was spiked into cell culture medium (Fig. S2).

Within-day variations of the ELISA were determined by the analysis of a dilution series of cell culture supernatant of MDA-MB-231 as Cyr61-positive samples. As Cyr61 negative samples, cell culture supernatant of MCF-7 was analyzed. Two different plates were analyzed on each day in a time series. For each measurement value of one day, the average value and the standard deviation were determined. The variation coefficient was determined by standard deviation divided by the average value (Table S1).

2.6. Immunocytochemical staining

The subcellular localization of CYR61 was analyzed by immunocytochemical double staining of CYR61 with keratin. The cell line HCC-366 was seeded in chamber slides (Nunc Lab-Tek Chamber Slide system, 2-Well Permanox Slide, Thermo Scientific) and cultured for 2 days (20 000 cells per well). The cell culture medium was removed and the cells were washed with PBS, followed by fixation of the cells by 2% paraformaldehyde for 10 min and a washing step using PBS (3 min). Cell permeabilization was done using 0.1% Triton X-100 in PBS for 10 min. Remaining Triton X-100 was removed by two washing steps with PBS for 3 min each. Unspecific binding sites were blocked using 10% AB-serum (Biotest, Dreieich, Germany) in PBS for 20 min. As primary anti-CYR61 antibody, the antibody H2 (Santa Cruz Biotechnology, Dallas, TX, USA) was used in a dilution of 1 : 100 in 10% AB-serum/PBS. The primary anti-Cyr61 remained for 60 min on the cells. Next, by three washing steps with PBS for 3 min (each step), residual antibody was removed. Application of a secondary rabbit anti-mouse fluorochrome antibody (546 nm, Molecular Probes, Eugene, OR, USA) was used for the revealing of the anti-CYR61 antibody. The secondary antibody was used in a 1 : 200 dilution. The diluent was 10% AB-serum/PBS, and the antibody was applied to the cells for 45 min. Unbound secondary antibody was removed by three washing steps with PBS.

For the detection of keratin, an antikeratin-specific antibody combination was applied consisting of the anti-pan-keratin antibody (mouse monoclonal, clone AE1/AE3; Thermo Scientific) and the anti-pan-keratin antibody C11 (mouse monoclonal; Cell Signaling Technology). To minimize interference with the anti-CYR61 staining, the antikeratin antibodies were applied as a direct-conjugate with Alexa Fluor 488. The antibodies were diluted with 10% AB-Serum in PBS applying a 1 : 100 dilution for C11 and a 1 : 80 dilution for the AE1/AE3 cocktail. The nuclei were stained using the DNA-specific probe 4’,6-diamidino-2-phenylindole (Dapi, Sigma, Munich, Germany). Dapi was applied in a final concentration of 1 µg·mL⁻¹ and was incubated for 60 min on the cells. Residual Dapi was removed by three washing steps. After mounting of the cells by ProLong Gold Antifade Mountant (Thermo Scientific), the cells were analyzed.
using the microscope Axioplan 2 (Carl Zeiss AG, Oberkochen, Germany).

2.7. Study population and blood collection

Eighty-seven LC patients were recruited at the Helios Clinic Emil von Behring, Berlin, Germany. All participants provided written informed consent. The study was designed according to the rules guarding patient privacy and with the approval from the ethics committee of the Ruhr University Bochum (reference number 3217-08). Peripheral blood of patients with diagnosed LC was drawn using 9.0 mL S-Monovette K2-EDTA gel tubes (Sarstedt, Nümbrecht, Germany). Plasma was obtained by centrifugation at 2000 g for 10 min at room temperature within 30 min after phlebotomy. Plasma was frozen immediately at −20 °C. Samples were regularly transported to the Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), aliquoted, and stored at −80 °C. For the analysis of CYR61, frozen samples were transported to the Department of Tumor Biology, University Medical Center Hamburg-Eppendorf.

In total, the study included 150 healthy controls. The blood of 140 healthy controls was obtained from the Department of Transfusion Medicine, University Medical Center Hamburg-Eppendorf. A history of cancer was excluded as part of the mandatory entry procedure for blood donors. The human investigations were performed according to the Helsinki rules after approval was obtained by the ethics committee of the Medical Association Hamburg (reference number PV5392). From all patients, written informed consent was obtained. Peripheral blood of healthy controls was drawn using 9.0 mL S-Monovettes K3E (Sarstedt). Plasma was obtained by centrifugation at 2000 g for 20 min at 4 °C. Plasma was subsequently aliquoted and stored at −80 °C until analysis of CYR61. Additionally, plasma samples from ten healthy current smokers were purchased from BioCat (Heidelberg, Germany) and included into the group of healthy controls. Samples were stored at −80 °C.

We carried out a retrospective study. Eligibility criteria were as follows: 18 years and older; men/women. LC samples were collected between September 2010 and November 2016 and healthy controls between July 2017 and March 2018. The identification of the LC patients was done by prior diagnosis and the cases formed a consecutive series. As a reference standard, healthy male and female individuals with an age of more than 50 years were selected (age-matched to the patients). Further information on healthy controls is not available.

2.8. Enzyme-linked immunosorbent assay (ELISA)

For the sandwich ELISA, the wells were first coated with the catching antibody, which was the anti-CYR61 antibody H2 (Santa Cruz Biotechnology). The antibody was allowed to bind to the surface of the wells 4 °C overnight with gentle agitation. Unbound antibody was removed with three washing steps using phosphate-buffered saline with 0.02% Tween-20 (PBST). Next, unspecific binding was blocked with blocking buffer (5% nonfat dry milk in PBST) followed by three washing steps with PBST. For the application of the plasma samples, the wells were first filled with 95 µL of DMEM with 10% FCS followed by application of 5 µL of the plasma to each well. The assay was incubated for 2 h at room temperature with gentle agitation. Subsequently, three washing steps with PBST were performed and the anti-CYR61 antibody H78 (Santa Cruz Biotechnology) was added to the wells. The incubation of this detecting antibody was performed at room temperature with gentle agitation for 2 h. Residual antibody was removed by three washing steps with PBST. For detection of CYR61, a polyclonal goat anti-rabbit immunoglobulin antibody coupled with horseradish peroxidase (DAKO) was applied to each well. Unbound secondary antibody was removed by three washing steps with PBST. Chromogenic detection was performed by using 3,3′,5,5′-tetramethylbenzidine (TMB). TMB one component HRP microwell substrate was purchased from (Bethyl Laboratories, Montgomery, USA) for 12 min followed by stopping the reaction by 100 µL of stop solution for TMB Substrates (ImmunoChemistry Technologies, Bloomington, IN, USA). For the detection of the extinction, the ELISA reader NanoQuant infinite M200 pro (Tecan, Männedorf, Switzerland) was used. The OD values were converted to CYR61 concentrations using recombinant and purified CYR61 protein from Abnova (Taipei, Taiwan) as a standard.

2.9. Statistical analysis

Arithmetic mean and standard deviation were used to describe the distribution of the CYR61 concentrations in the study groups. Groups were compared using the nonparametric Mann–Whitney U-test or the Kruskal–Wallis test (with \( P < 0.05 \) as statistically significant). Furthermore, boxplots with median, interquartile range (IQR), and whiskers represent minimum and maximum display CYR61 concentrations. Sensitivity and specificity were determined from receiver operating characteristic (ROC) curves illustrating the performance of
to discriminate the studied groups. The area under the curve (AUC) was determined with its 95% Wald confidence interval (CI). Biomarker cut-offs were determined with maximum Youden's index (YI, \( YI = \text{sensitivity} + \text{specificity} - 100 \)) or at a predefined specificity of 100%. The parameters AUC, sensitivity and specificity were used for the determination of diagnostic accuracy. Statistical analyses were performed either using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA) or ORIGINPRO version 9.6.5.169 (OriginLab Corporation). Figures were generated with PRISM 7 (GraphPad Software, La Jolla, CA, USA). All data analyzed during this study are included in Table S2.

3. Results

3.1. Detection of CYR61 in cell lines and peripheral blood mononuclear cells (PBMC)

Starting with cell line models, we detected cytoplasmic CYR61 in LC cell lines by Western Blot (Fig. 1A). HCC-366 was strongly positive for CYR61, whereas lower concentrations were detected in H1993. No signal could be detected for H1299 and H1395.

One of the preferred receptors of CYR61 is the integrin \( \alpha v/\text{integrin} \beta 3 \) heterodimer. These two integrins were present in the strongly CYR61-positive LC cell line HCC-366, while the other cell lines lacked detectable amounts of integrin \( \beta 3 \).

As prerequisite for the subsequent measurement in clinical samples, we measured cytoplasmic and secreted CYR61 concentrations in LC cell lines by ELISA (Fig. 1B). A cytoplasmic CYR61 amount of 161.8 pg per \( \mu \)g cell lysate was detected for HCC-366 and 12.3 pg per \( \mu \)g cell lysate for H1993. No signals were detected in lysates from H1299 and H1395. For secreted CYR61, a concentration of 1190 ng/mL for HCC-366 and 350 ng/mL for H1993. For H1299 and H1395, 1 ng/mL CYR61 was detected.

Next, we investigated the CYR61 secretion kinetics (Fig. 1C). We replaced the cell culture medium from flasks with confluent cells by fresh medium and determined the released CYR61 concentration in the cell culture supernatant. Besides H1993, we analyzed the cell culture supernatant of the LC bone marrow DTC cell line LC-M1. We observed that H1993 quickly released CYR61 into the medium reaching a plateau with a CYR61 amount of about 4 pg per cell after 1 h. For LC-M1, a more continuous CYR61 secretion was observed, reaching a CYR61 concentration of approximately 2 pg per cell after 5 h.

We then determined the subcellular distribution of CYR61 in HCC-366 and observed that CYR61 was distributed as cytoplasmic granules and was frequently

Fig. 1. Detection of CYR61 and its secretion in lung cancer cells. All experiments \( n = 3 \). (A) Identification of CYR61-positive lung cancer cell lines by western blot. (B) Quantification of the cytoplasmic CYR61 concentrations (diagram left) and secreted CYR61 (diagram right) by ELISA. The values are the average of three independent experiments, and vertical error bars show the standard deviation. (C) CYR61 secretion rates of H1993 and LC-M1 calculated as mass of secreted CYR61 in picogram per cell. (D) Subcellular localization of CYR61 in the non-small lung cancer cell line HCC-366. The composite image is an overlay of the DAPI, cytokeratin, and CYR61 signals. c, concentration; CYR61, cysteine-rich angiogenic inducer 61; h, hour; m, mass; MW, molecular weight; n, number of biologically independent replicates.
Table 1. Clinico-pathological parameters of lung cancer patients and concentrations of CYR61 in the plasma of lung cancer patients stratified by sex.

|                | Total n | c(CYR61) [ng·mL⁻¹] | P-valueb | Men n | c(CYR61) [ng·mL⁻¹] | P-valueb | Women n | c(CYR61) [ng·mL⁻¹] | P-valueb |
|----------------|---------|---------------------|----------|-------|---------------------|----------|---------|---------------------|----------|
| Age at the time of blood sampling |         |                     |          |       |                     |          |         |                     |          |
| < 50           | 5       | 4.5 ± 9.8           | 0.3125   | 43    | 25.1 ± 20.0         | 0.3517   | 44      | 2.6 ± 6.6          | 0.0062   |
| 50–60          | 16      | 14.6 ± 19.7         | 0.00084  |       |                     |          |         |                     |          |
| 60–70          | 30      | 12.5 ± 20.2         |          |       |                     |          |         |                     |          |
| 70–80          | 30      | 17.6 ± 18.5         |          |       |                     |          |         |                     |          |
| ≥ 80           | 6       | 6.3 ± 10.5          |          |       |                     |          |         |                     |          |
| Sex            |         |                     |          |       |                     |          |         |                     |          |
| Male           | 43      | 25.1 ± 20.0         |          |       |                     |          |         |                     |          |
| Female         | 44      | 2.6 ± 6.6           |          |       |                     |          |         |                     |          |
| Smoking status |         |                     |          |       |                     |          |         |                     |          |
| Never          | 9       | 0.3 ± 0.6           | 0.0052   |       |                     | 0.0724   | 9       | 0.3 ± 0.6          | 0.7389   |
| Former         | 58      | 17.6 ± 20.3         |          |       |                     |          | 33      | 27.8 ± 20.7        | 0.0084   |
| Current        | 20      | 8.5 ± 13.3          |          |       |                     |          | 10      | 16.4 ± 15.2        | 0.1673   |
| Histology      |         |                     |          |       |                     |          |         |                     |          |
| Adenocarcinoma | 49      | 13.5 ± 19.3         | 0.0476   | 19    | 29.0 ± 21.8         | 0.4686   | 30      | 3.6 ± 7.8          | 0.1084   |
| Small cell carcinoma | 10   | 21.5 ± 25.2         |          |       |                     |          | 10      | 21.5 ± 25.2        |          |
| Squamous cell carcinoma | 22   | 14.4 ± 14.7         |          |       |                     |          | 14      | 22.4 ± 12.7        |          |
| Others         | 6       | 0.3 ± 0.5           |          |       |                     |          | 0       | 0.3 ± 0.5          |          |
| Stage          |         |                     | 0.8261   |       |                     | 0.9031   |         |                     | 0.0779   |
| IIB            | 4       | 9.0 ± 10.8          |          |       |                     |          | 2       | 17.9 ± 5.2         |          |
| IIIA           | 13      | 18.3 ± 17.5         |          |       |                     |          | 9       | 26.4 ± 14.8        |          |
| IIIIB          | 11      | 14.4 ± 20.4         |          |       |                     |          | 6       | 22.4 ± 24.4        |          |
| IV             | 59      | 12.9 ± 19.1         |          |       |                     |          | 26      | 25.9 ± 21.8        |          |
| T-stage        |         |                     | 0.6340   |       |                     | 0.7870   |         |                     | 0.0273   |
| 1              | 3       | 20.4 ± 34.8         |          |       |                     |          | 2       | 30.4 ± 42.7        |          |
| 2              | 28      | 10.8 ± 16.2         |          |       |                     |          | 13      | 20.8 ± 18.2        |          |
| 3              | 23      | 13.2 ± 14.3         |          |       |                     |          | 14      | 21.7 ± 12.2        |          |
| 4              | 33      | 15.9 ± 21.9         |          |       |                     |          | 14      | 31.8 ± 24.9        |          |
| Nodal status   |         |                     | 0.6613   |       |                     | 0.5673   |         |                     | 0.1564   |
| 0              | 4       | 5.4 ± 6.7           |          |       |                     |          | 2       | 10.6 ± 5.2         |          |
| 1              | 11      | 17.9 ± 15.1         |          |       |                     |          | 7       | 20.5 ± 15.5        |          |
| 2              | 41      | 14.3 ± 20.4         |          |       |                     |          | 21      | 27.5 ± 21.3        |          |
| 3              | 31      | 12.5 ± 18.4         |          |       |                     |          | 13      | 26.0 ± 21.6        |          |
| Metastasis     |         |                     | 0.1673   |       |                     | 0.3458   |         |                     | 0.0135   |
| 0              | 28      | 15.5 ± 17.7         |          |       |                     |          | 17      | 24.0 ± 17.5        |          |
| 1a             | 20      | 18.3 ± 23.1         |          |       |                     |          | 10      | 32.7 ± 24.5        |          |
| 1b             | 39      | 10.1 ± 16.4         |          |       |                     |          | 16      | 21.6 ± 19.6        |          |

*Arithmetic mean ± standard deviation.
*Kruskal–Wallis test.

found adjacent to the nucleus (Fig. 1D). Keratin staining was performed to visualize the cell shape.

3.2. Characteristics of the clinical study

We investigated 43 male and 44 female LC patients, comprising 49 ADC, 22 SCC, 10 SCLC, and 6 other LCs (Table 1). The healthy controls consisted of 58 men and 92 women. The distribution of circulating CYR61 in the plasma is presented in Fig. 2. CYR61 concentrations in plasma were elevated in all LC patients (13.7 ± 18.6 ng·mL⁻¹) compared with all healthy controls (0.29 ± 0.22 ng·mL⁻¹; *P* = 0.0003). Analysis of sex-specific differences revealed that CYR61 concentrations were higher in male LC patients (25.1 ± 20.0 ng·mL⁻¹) compared with male healthy controls (0.28 ± 0.22 ng·mL⁻¹; *P* < 0.0001). CYR61 concentrations were lower in female LC patients (2.6 ± 6.6 ng·mL⁻¹) compared with male LC patients but they remained elevated compared with...
CYR61 concentrations in healthy women (0.30 ± 0.23 ng·mL⁻¹, \( P = 0.0054 \)).

### 3.3. Correlation of the CYR61 concentrations with clinical parameters

We analyzed potential correlations of CYR61 with clinico-pathological parameters (Table 1). We found an association of the CYR61 concentrations with sex (\( P = 0.0084 \)), smoking status (\( P = 0.0052 \)), and cancer histology (\( P = 0.0476 \)).

Since we found large differences between CYR61 concentrations in men and women, it seems reasonable to consider both sexes separately. In men, smoking status showed a marginal effect on CYR61 concentration (\( P = 0.0724 \)). In women, CYR61 concentrations differed between age groups (\( P = 0.0062 \)), T-stage (\( P = 0.0273 \)), and metastasis status (\( P = 0.0135 \)). In contrast, the found association between CYR61 concentration and cancer histology in the total study population might rather be an expression of the sex-specific CYR61 difference (\( P = 0.0476 \)). For the other clinical parameters, no statistically significant association was observed.

### 3.4. Receiver operating characteristic (ROC) analyses of CYR61 concentrations in plasma

Results of the ROC analyses of CYR61 concentrations in plasma are presented in Fig. 3 and Table 2. For the comparison of all LC patients vs. all healthy controls, we obtained an AUC of 0.641 (95% CI 0.549–0.733). Using the maximum YI, a sensitivity of 54% at 99% specificity was revealed. Comparing male LC patients...
vs. male controls, an improved AUC of 0.932 (95% CI 0.872–0.993) with a sensitivity of 84% at 100% specificity was obtained (maximum YI). In contrast, an inferior performance was observed for females (AUC = 0.352 (95% CI 0.227–0.478); sensitivity: 27%; specificity: 99%; maximum YI).

### 4. Discussion

We investigated the potential of circulating CYR61 in plasma as a biomarker for the detection of LC. Firstly, we confirmed by western blot and immunostaining that LC cells are able to express cellular CYR61. Cell line HCC-366 showed strong expression of cellular CYR61 together with strong expression of integrin αvβ3, which is known as direct receptor for CYR61 [46]. It was shown that CYR61 stimulates direct chemotaxis [47] and Tsai et al. [33] proposed that CYR61 can mediate tumor growth and angiogenesis in either an autocrine or paracrine manner through its binding to the αvβ3 integrin receptor. These findings could possibly explain the difference in expression level between HCC-366 and H1993 since H1993 cell line showed no expression of integrin β3 and weak expression of cellular CYR61 in our experiments. Cell lines H1299 and H1395 showed no expression of both, CYR61 and integrin β3. Subsequent ELISA analysis showed that LC cells are also secreting CYR61 protein with HCC-366 showing the highest level of secretion.

After demonstrating in vitro that LC cells express and secrete substantial amounts of CYR61, we also detected circulating CYR61 concentrations in plasma samples from LC patients. Our results revealed a significant positive association of the CYR61 plasma concentration with smoking status; current and former smokers had elevated CYR61 concentrations compared with never smokers. The higher concentration in current smokers is consistent with the view that CYR61 is a tissue stress sensor [48–50]. However, the rather small sizes of the study groups and an unequal distribution of current, former, and never smokers, as well as all never smokers in our cohort were women, could lead to artificially decreased concentration of CYR61 in the group of never smokers and therefore lead to misconclusions. In line with this, we could not find statistically significantly different CYR61 concentrations depending on smoking status in the group of female LC patients. Therefore, the role of smoking status and sex on CYR61 concentrations needs to be further elucidated.

Additionally, we found an association between CYR61 concentrations and histological subtype but this observation might be based on an uneven distribution of histology between sexes. For example, the study group for SCLC comprises only of male participants which could lead to an artificial increase in CYR61 concentration when both sexes are combined together. Hence, the association between CYR61 concentration and histological subtype should be further investigated. However, this result is consistent with a previous report from Chen et al. [21]. On the other hand, Mori et al. [24] reported no correlation between CYR61 expression level and histological subtype. It
should be noted that in both works tissue samples have been analyzed, whereas we analyzed circulating CYR61 in plasma. Therefore, future studies are needed also in order to compare the expression of CYR61 in tissues with circulating CYR61.

Our key finding was the high sensitivity and specificity of circulating CYR61 concentrations for detection of LC in men. Stratification by sex revealed a sensitivity of 84% for men compared with only 27% for women at high specificities of 100% and 99%, respectively. The mechanism behind this sex-specific difference remains unclear. However, previous studies have reported sex-specific actions of other biomarkers in LC possibly due to endocrine difference involving the estrogen signaling axis [51,52]. It has been reported previously that estrogen and CYR61 are promoting cancer progression through the Hippo signaling pathway [29,53,54]. Therefore, it is possible that cancer

Table 3. Comparison of the accuracy of different blood tests used for the detection of lung cancer.

| Analyte | Patient criterion | Sensitivity | Specificity | Study description | Reference |
|---------|------------------|-------------|-------------|--------------------|-----------|
| CTCs Inclusion criteria: NLST-UPSTF criteria plus COPD defined as persistent respiratory symptoms and fixed airflow limitation with a postbronchodilator FEV1/forced vital capacity < 0.7 Exclusion criteria: any cancer, other than basalcellular skin carcinoma, detected within the previous 5 years. Full exclusion criterion is reported in Leroy et al. [60] | | | | Participants underwent three screenings at 1-year intervals. Each screening round consisted of a clinical examination, a LDCT, and a blood test to detect CTCs (ISET Rarecells; Rarecells Diagnostics, Paris, France). The primary endpoint of the study was the diagnostic performance of CTC detection as a biomarker for diagnosis of lung cancer screening, could CTC detection act as a screening tool? For this purpose, the detection of CNHC-malignant and CNHC-uncertain was considered as positive for cancer diagnosis | [13] |
| ctDNA Inclusion criteria: (i) NSCLC stage III-IV (ii) the selected patients were diagnosed both histopathologically and cytologically (iii) the data on TP, TN, FP and FN were fully reported to construct 2 x 2 table (iv) the EGFR mutation was detected Exclusion criteria: (i) Peripheral blood and tumor tissues were not paired (ii) the case sample number was < 10 in the case series studies (iii) the study did not clarify the tumor stage and the data of advanced NSCLC could not be extracted | | | Meta-analysis of the value of peripheral blood ctDNAs in detection of EGFR mutations in patients with advanced NSCLC. A total of 32 studies were finally included in the meta-analysis | [61] |
| miRNA LC patients I-IV stage (NSCLC, SCLC) (n = 606) Control group (n = 2440): patients with other lung diseases, patients with other diseases not affecting lungs, unaffected control participants Inclusion criterion: symptomatic patients, available definitive clinical diagnosis | | | Signature of 15 mRNA was identified to distinguish patients diagnosed with lung cancer from all other individuals (patients with other lung diseases, patients with other diseases not affecting lungs and unaffected control participants) | [62] |
| CYR61 protein (in men) LC patients II-IV stage Inclusion criteria: ≥ 18 men Control group: healthy male individuals with an age >50 years (age-matched to the patients) | | | The identification of the lung cancer patients was done by prior diagnosis | Our study |

CI, confidence interval; CNHC-malignant, circulating nonhematological cells with malignant features; CNHC-uncertain, circulating nonhematological cells with uncertain malignant features; CTC, circulating tumor cells; ctDNA, circulating tumor DNA; FN, false negative; FP, false positive; TN, true negative; TP, true positive.
progression is driven via the effect of estrogen in females while in men it is rather driven by CYR61 instead of estrogen. Previous immunohistochemical analyses of CYR61 expression in LC tissue have not revealed significant sex-specific differences [21,24]. Besides technical reasons (e.g., choice of antibodies, fixation of tissue), this might be explained by the assumption that CYR61 secretion into the blood is not only determined by the cytoplasmic protein content of CYR61 but also involves other factors with an impact on the release of CYR61 into the blood. This hypothesis is in line with our recent report on CYR61 secretion in breast cancer [55], and it might stimulate future experimental work. Comparing CYR61 with other blood biomarkers of the liquid biopsy family, such as CTCs, ctDNA, and miRNA, showed that CYR61 has rather higher sensitivity and specificity for the detection of LC (Table 3). Moreover, CYR61 protein is relatively stable in plasma [56] and CYR61 concentrations can be easily measured by ELISA at low costs with very small amounts of plasma. Additionally, ELISA is an established method useful for screening routine in a central laboratory. On the other hand, no isolation method for the analysis of LC-derived CTCs, ctDNA, or miRNA has been standardized yet and isolation methods that are currently being used are either time-consuming or are suffering from large yield variations, low sensitivity, low purity, or low recovery rate [57–59] compared with isolation of plasma and detection of secreted proteins. However, the advantage of the use of other analytes compared with secreted proteins, such as CYR61, is further molecular analysis after detection.

Limitation of this study is that our study population consisted of LC patients at advanced stage, whereas samples from individuals with pulmonary nodules or early-stage LC samples were missing. However, for the detection of LC at early stages, CYR61 should be validated in plasma samples taken before clinical diagnosis using a large study with a prospective design.

5. Conclusions

Our present pilot study suggests that circulating CYR61 protein has the potential to serve as a new biomarker for the detection of LC in men. However, this proof-of-principle finding needs to be validated in appropriate prospective studies. Additionally, CYR61 is significantly elevated in female LC patients but sensitivity and specificity for CYR61 are too low for the improvement of the detection of lung cancer in women.

Acknowledgements

The authors thank York Hildebrandt and Nina Rosenkranz for excellent technical support. L.A. and K.P. were financially supported by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 765492, K.P. This work was supported by the Kastner-Foundation (K.P.). The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, preparation of manuscript, or final approval of the manuscript. Open Access funding enabled and organized by Projekt DEAL.

Conflict of interest

KB and KP are inventors of patent applications including the use of CYR61 for early detection of breast cancer (No. EP1715 7020; No. PCT/EP2018/054052), otherwise no competing interests.

Author contributions

All authors approved the final version manuscript. All authors are accountable for all aspects of the work. LA, KB, DGW, GJ, and KP involved in experimental design and manuscript writing. KB, LA, and AA performed experiments. KB, DGW, IR, TB, JK, MG, SP, and GJ involved in analysis of plasma samples & data analysis. SC carried out Statistics.

Peer Review

The peer review history for this article is available at https://publons.com/publon/10.1002/1878-0261.13099.

Data accessibility

All data are available within the main text and supporting material.

References

1 WHO (2020) Report on Cancer Deaths. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed on 22nd of September 2021.
2 Du M, Thompson J, Fisher H, Zhang P, Huang CC & Wang L (2018) Genomic alterations of plasma cell-free
DNAs in small cell lung cancer and their clinical relevance. *Lung Cancer* **120**, 113–121.
3 Osmani L, Askim F, Gabrielson E & Li QK (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. *Semin Cancer Biol* **52**, 103–109.
4 Weiss G, Schlegel A, Kottwitz D, König T & Tetzner R (2017) Validation of the SHOX2:PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. *J Thorac Oncol* **12**, 77–84.
5 Oudkerk M, Liu S, Heuvelmans MA, Walter JE & Oudkerk M, Liu S, Heuvelmans MA, Walter JE & (2017) Circulating tumor cells in non-small cell lung cancer: a new medium of liquid DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer. *Cancers* **12**, 1147.
6 Li Y, Jiang BY, Gao M, Yang JJ, Zhang XC, Zhang Z, Ye JJ, Zhong WZ, Tu HY, Chen HJ, Wang Z et al. (2018) Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy. *Ann Oncol* **29**, 945–952.
7 Mao X, Zhang Z, Zheng X, Xie F, Duan F, Jiang L, Chuai S, Han-Zhang H, Han B & Sun J (2017) Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. *J Thorac Oncol* **12**, 663–672.
8 Yang M, Topaloglu U, Petty WJ, Pagni M, Foley KL, Grant SC, Robinson M, Bitting RL, Thomas A, Alistar AT et al. (2017) Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. *J Hematol Oncol* **10**, 100.
9 Heidrich I, Ackar L, Mossahebi Mohammadi P & Pantel K (2021) Liquid biopsies: potential and challenges. *Int J Cancer* **148**, 528–545.
10 Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud JM, Padovani B, Mouroux J, Marquette CH & Hofman P (2014) "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. *PLoS One* **9**, e111597.
11 Marquette CH, Boutros J, Benzaquen J, Ferreira M, Pastre J, Pison C, Padovani B, Bettayeb F, Fallet V, Guibert N et al. (2020) Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. *Lancet Respir Med* **8**, 709–716.
12 Mannan J, Mitchell JB, Suvilehto KN, Avella DM, Kimchi ET, Staveley-O’Carroll KF, Deroche CB, Pantel K, Li G & Kaifl JT (2020) Circulating giant tumor-macrophage fusion cells are independent prognosticators in patients with NSCLC. *J Thorac Oncol* **15**, 1460–1471.
13 Anfossi S, Babayan A, Pantel K & Calin GA (2018) Clinical utility of circulating non-coding RNAs – an update. *Nat Rev Clin Oncol* **15**, 541–563.
14 Sol N & Wurdinger T (2017) Platelet RNA signatures for the detection of cancer. *Cancer Metastasis Rev* **36**, 263–272.
15 Elzanowska J, Semira C & Costa-Silva B (2020) DNA in extracellular vesicles: biological and clinical aspects. *Mol Oncol* **15**, 1701–1714.
16 Fahrmann JF & Mao X (2020) Plasma-derived extracellular vesicles convey protein signatures that reflect pathophysiology in lung and pancreatic adenocarcinomas. *Cancers* **12**, 1147.
17 Hoshino A, Kim HS, Bojmar L, Gyan KE, Cioffi M, Hernandez J, Zambrinis CP, Rodrigues G, Molina H, Heissel S et al. (2020) Extracellular vesicle and particle biomarkers define multiple human cancers. *Cell* **182**, 1044–1061.e1018.
18 Rijavec E & Coco S (2019) Liquid biopsy in non-small cell lung cancer. *Highlights Chal* **12**, 17.
19 Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ & Xie D (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung nodules. *JAMA Intern Med* **167**, 1061.e1018.
20 Huang YT, Lan Q, Lorusso G, Duffey N & Rüegg C (2017) The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis. *Oncotarget* **8**, 9200–9215.
21 Jandova J, Beyer TE, Meuillet EJ & Watts GS (2012) The matrix protein CCN1/CYR61 is required for α(V)β5-mediated cancer cell migration. *Cell Biochem Funct* **30**, 687–695.
22 Mori A, Desmond JC, Komatsu N, O’Kelly J, Miller CW, Legaspi R, Marchevsky AM, McKenna RJ Jr & Koeffler HP (2007) CYR61: a new measure of lung cancer outcome. *Cancer Invest* **25**, 738–741.
23 Tong X, Xie D, O’Kelly J, Miller CW, Muller-Tidow C & Koeffler HP (2001) Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer. *J Biol Chem* **276**, 47709–47714.
24 Tong X, O’Kelly J, Xie D, Mori A, Lemp N, McKenna R, Miller CW & Koeffler HP (2004) Cyr61 suppresses the growth of non-small-cell lung cancer cells via the
beta-catenin-c-myc-p53 pathway. Oncogene 23, 4847–4855.

27 Zhu Y, Almuntashiri S, Han Y, Wang X, Somanath PR & Zhang D (2020) The roles of CCN1/CYR61 in pulmonary diseases. Int J Mol Sci 21, 7810.

28 Li X, Yuan N, Lin L, Yin L & Qu Y (2018) Targeting cysteine-rich angiogenic inducer-61 by antibody immunotherapy suppresses growth and migration of non-small cell lung cancer. Exp Ther Med 16, 730–738.

29 Hsu PC, Miao J, Huang Z, Yang YL, Xu Z, You J & Dai Y (2018) Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. J Cell Mol Med 22, 3073–3085.

30 Zhang D, Zhang Y, Cai Z, Tu Y & Hu Z (2020) Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways. Exp Ther Med 19, 762–770.

31 Bartkowiak K, Casjens S, Andreas A, Ackar L, Joosse SA, Raiko I, Brünig T, Geffken M, Peine S, Johnen G et al. (2020) Sensitive blood-based detection of asbestos-associated diseases using cysteine-rich angiogenic inducer 61 as circulating protein biomarker. Clin Chem 67, 363–373.

32 O’Kelly J, Chung A, Lemp N, Chamakova K, Yin D, Wang HJ, Saïd J, Gui D, Miller CW, Karlan BY et al. (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33, 59–67.

33 Tsai MS, Bogart DF, Castañeda JM, Li P & Lupu R (2002) Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21, 8178–8185.

34 Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popovicu ML, Said JW et al. (2005) Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 11, 7243–7254.

35 Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH et al. (2005) Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 11, 5809–5820.

36 Lin MT, Kuo IH, Chang CC, Chu CY, Chen HY, Lin BR, Sureshbabu M, Shih HJ & Kuo ML (2008) Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem 283, 15807–15815.

37 Xie D, Yin D, Tong X, O’Kelly J, Mori A, Miller C, Black K, Gui D, Said JW & Koeffler HP (2004) Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 64, 1987–1996.

38 Young N & Van Brocklyn JR (2007) Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res 313, 1615–1627.

39 Huang YT, Lan Q, Ponsonnet L, Blanquet M, Christofori G, Zaric J & Rüegg C (2016) The matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progression. Oncotarget 7, 1663–1674.

40 Bartkowiak K, Effenberger KE, Harder S, Andreas A, Buck F, Peter-Katalinic J, Pantel K & Brandt BH (2010) Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients. J Proteome Res 9, 3158–3168.

41 Pantel K, Dickmanns A, Zippelius A, Klein C, Shi J, Hoechtl-Vollmar W, Schlimok G, Weckermann D, Oberneder R, Fanning E et al. (1995) Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 87, 1162–1168.

42 Bartkowiak K, Kwiatkowski M, Buck F, Gorges TM, Nilse L, Assmann V, Andreas A, Müller V, Wikman H, Riethdorf S et al. (2015) Disseminated tumor cells persist in the bone marrow of breast cancer patients through sustained activation of the unfolded protein response. Cancer Res 75, 5367–5377.

43 Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zänker KS, Brandt BH & Dittmar T (2012) The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination. J Pathol 227, 234–244.

44 Putz E, Witter K, Öffner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmüller G & Pantel K (1999) Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 59, 241–248.

45 Willipinski-Stampelfeld B, Riethdorf S, Assmann V, Woelffle U, Rau T, Sauter G, Heukenhoven J & Pantel K (2005) Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 11, 8006–8014.

46 Kireeva ML, Lam SC & Lau LF (1998) Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 273, 3909–3906.

47 Babic AM, Kireeva ML, Kolesnikova TV & Lau LF (1998) CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 95, 6355–6360.
Detection of lung cancer by CYR61

L. Ackar et al.

48 Jin Y, Kim HP, Ifedigbo E, Lau LF & Choi AM (2005) Cyr61 protects against hyperoxia-induced cell death via Akt pathway in pulmonary epithelial cells. Am J Respir Cell Mol Biol 33, 297–302.

49 Schild C & Trueb B (2004) Three members of the connective tissue growth factor family CCN are differentially regulated by mechanical stress. Biochim Biophys Acta 1691, 33–40.

50 Yoshida Y, Togi K, Matsumae H, Nakashima Y, Kojima Y, Yamamoto H, Ono K, Nakamura T, Kita T & Tanaka M (2007) CCN1 protects cardiac myocytes from oxidative stress via beta1 integrin-Akt pathway. Biochem Biophys Res Commun 355, 611–618.

51 Shin JY, Jung HJ & Moon A (2019) Molecular markers in sex differences in cancer. Toxicol Res 35, 331–341.

52 Li CH, Haider S, Shiah YJ, Thai K & Boutros PC (2018) Sex Differences in cancer driver genes and biomarkers. Cancer Res 78, 5527–5537.

53 Zhu C, Li L, Zhang Z, Bi M, Wang H, Su W, Hernandez K, Liu P, Chen J, Chen M et al. (2019) A non-canonical role of YAP/TEAD is required for activation of estrogen-regulated enhancers in breast cancer. Mol Cell 75, 791–806.e798.

54 Britschgi A, Duss S, Kim S, Couto JP, Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z et al. (2017) The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERx. Nature 541, 541–545.

55 Bartkowiak K, Heidrich I, Kwiatkowski M, Gorges TM, Andreas A, Geffen M, Verpoort K, Muller V, Schluter H & Pantel K (2021) Cysteine-rich angiogenic inducer 61: pro-survival function and role as a biomarker for disseminating breast cancer cells. Cancers 13, 563.

56 Yang GP & Lau LF (1991) Cyr61, product of a growth factor-inducible immediate gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 2, 351–357.

57 Lara O, Tong X, Zborowski M & Chalmers JJ (2004) Enrichment of rare cancer cells through depletion of normal cells using density and flow-through, immunomagnetic cell separation. Exp Hematol 32, 891–904.

58 Ferreira MM, Ramani VC & Jeffrey SS (2016) Circulating tumor cell technologies. Mol Oncol 10, 374–394.

59 Elaeezy M & Joosse SA (2018) Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J 16, 370–378.

60 Leroy S, Benzaquen J, Mazzetta A, Marchand-Adam S, Padvani B, Israel-Biet D, Pison C, Chanez P, Cadranel J, Mazieres J et al. (2017) Circulating tumour cells as a potential screening tool for lung cancer (the AIR study); protocol of a prospective multicentre cohort study in France. BMJ Open 7, e018884.

61 Zhou S, Huang R & Cao Y (2020) Detection of epidermal growth factor receptor mutations in peripheral blood circulating tumor DNA in patients with advanced non-small cell lung cancer: a PRISMA-compliant meta-analysis and systematic review. Medicine 99, e21965.

62 Fehlmann T, Kahraman M, Ludvig N, Backes C, Galata V, Keller V, Geffers L, Mercaldo N, Hornung D, Weis T et al. (2020) Evaluating the use of circulating microRNA profiles for lung cancer detection in symptomatic patients. JAMA Oncol 6, 714–723.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Fig. S1. Calibration curves for the conversion of the OD values to the Cyr61 amount in this study.

Fig. S2. Calibration curves for the conversion of the OD values to the Cyr61 amount for the cell line experiments.

Table S1. Variation coefficients of Cyr61 levels in a time course.

Table S2. Clinical data of the study.